Abstract
The cancer-testis antigen, NY-ESO-1, has been engineered into a bacterial expression plasmid which incorporates a His6-tag. The plasmid was transfected into E. coli strain BL21 and Master and Working cell banks generated from this expression system. Three 15-litre fermentations were performed under cGMP (code of Good Manufacturing Practice) conditions and the crude NY-ESO-1 tagged protein isolated as solubilised inclusion bodies. A three-step cGMP chromatography process (immobilised metal affinity, anion exchange, and hydrophobic interaction) was utilised to purify the protein. The purified NY-ESO-1 is being used in early stage human cancer vaccine trials in Australia and the U.S.A.
Original language | English |
---|---|
Pages (from-to) | 119-134 |
Number of pages | 16 |
Journal | Preparative Biochemistry & Biotechnology |
Volume | 35 |
Issue number | 2 |
DOIs | |
Publication status | Published - 10 May 2005 |
Keywords
- Cancer-testis antigen
- cGMP
- NY-ESO-1
- Recombinant protein